Cargando…
Clinical utility of the nuclear-localized AR-V7 biomarker for treatment choice in metastatic castration-resistant prostate cancer
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7807368/ https://www.ncbi.nlm.nih.gov/pubmed/33457221 http://dx.doi.org/10.21037/tau-20-968 |
| _version_ | 1783636728410537984 |
|---|---|
| author | Vlaeminck-Guillem, Virginie |
| author_facet | Vlaeminck-Guillem, Virginie |
| author_sort | Vlaeminck-Guillem, Virginie |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7807368 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-78073682021-01-15 Clinical utility of the nuclear-localized AR-V7 biomarker for treatment choice in metastatic castration-resistant prostate cancer Vlaeminck-Guillem, Virginie Transl Androl Urol Editorial Commentary AME Publishing Company 2020-12 /pmc/articles/PMC7807368/ /pubmed/33457221 http://dx.doi.org/10.21037/tau-20-968 Text en 2020 Translational Andrology and Urology. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Editorial Commentary Vlaeminck-Guillem, Virginie Clinical utility of the nuclear-localized AR-V7 biomarker for treatment choice in metastatic castration-resistant prostate cancer |
| title | Clinical utility of the nuclear-localized AR-V7 biomarker for treatment choice in metastatic castration-resistant prostate cancer |
| title_full | Clinical utility of the nuclear-localized AR-V7 biomarker for treatment choice in metastatic castration-resistant prostate cancer |
| title_fullStr | Clinical utility of the nuclear-localized AR-V7 biomarker for treatment choice in metastatic castration-resistant prostate cancer |
| title_full_unstemmed | Clinical utility of the nuclear-localized AR-V7 biomarker for treatment choice in metastatic castration-resistant prostate cancer |
| title_short | Clinical utility of the nuclear-localized AR-V7 biomarker for treatment choice in metastatic castration-resistant prostate cancer |
| title_sort | clinical utility of the nuclear-localized ar-v7 biomarker for treatment choice in metastatic castration-resistant prostate cancer |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7807368/ https://www.ncbi.nlm.nih.gov/pubmed/33457221 http://dx.doi.org/10.21037/tau-20-968 |
| work_keys_str_mv | AT vlaeminckguillemvirginie clinicalutilityofthenuclearlocalizedarv7biomarkerfortreatmentchoiceinmetastaticcastrationresistantprostatecancer |